Clinical Trial

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Name: A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON) — clinical trial record (NCT06978725)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BEACON

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Trial Details

NCT Number	NCT06978725
Lead Sponsor	Priovant Therapeutics, Inc.
Conditions	Cutaneous Sarcoidosis
Enrollment	28 participants
Start Date	2025-04-09
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-05-18